My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: usually no — compounded GLP‑1s are rarely the best first option. They can be tempting if insurance denies Wegovy, but they carry safety, quality, and legal/coverage downsides. There are safer, often cheaper alternatives and steps you should try first.

Why compounded GLP‑1s are risky

• Not FDA‑approved: quality, purity, potency, and sterility aren’t guaranteed the way they are for brand drugs. Peptide drugs (like semaglutide/tirzepatide) are especially sensitive to handling and formulation.
• Variable dosing and stability: increased risk of under‑ or overdosing and contamination.
• No formal adverse‑event surveillance or manufacturer support.
• Generally not covered by insurance and you’ll pay cash.
• Legal/regulatory gray area — some pharmacies won’t compound these products.

Better options to try first

1. Appeal the denial and ask your prescriber to help

   • Request a formal appeal / prior authorization review and provide a letter of medical necessity with BMI, comorbidities (HTN, sleep apnea, diabetes), previous weight‑loss attempts, and clinical notes.
   • Ask the prescriber to do a peer‑to‑peer review with the insurer if the first appeal fails.

2. Manufacturer patient assistance / savings

   • Wegovy (Novo Nordisk) often has a Wegovy Savings Card or patient support programs for commercially insured patients; check Novo Nordisk’s patient support. These can substantially lower out‑of‑pocket costs for eligible patients.
   • If you’re Medicare, note manufacturer coupons usually aren’t allowed.

3. Consider alternative FDA‑approved GLP‑1 or GLP/GIP options

   • Zepbound (tirzepatide, Eli Lilly) is FDA‑approved for chronic weight management and may be covered differently by some plans than Wegovy.
   • Ozempic (semaglutide, Novo Nordisk) and Rybelsus (oral semaglutide) are FDA‑approved for type 2 diabetes; some insurers cover them more readily (off‑label use for weight loss happens but coverage varies).
   • Mounjaro (tirzepatide, Eli Lilly) is approved for type 2 diabetes and sometimes used off‑label for weight; check coverage and discuss safety with your clinician.

4. Help lowering cash price

   • Use discount services like GoodRx or SingleCare to compare cash prices at local pharmacies; sometimes these are cheaper than paying the insurer denial out‑of‑pocket.
   • Ask your prescriber about prescribing alternatives with similar benefit that are more likely to be covered.

5. If you still consider compounded

   • Only use a reputable compounding pharmacy that is accredited (look for PCAB accreditation or state board accreditation).
   • Understand you’ll pay cash, there’s no FDA guarantee, and you should get documentation on sterility testing, potency testing, and expiry/stability.
   • Discuss risks with your clinician and document informed consent.

What I recommend you do next

• Talk with your prescriber now: ask them to submit an appeal/peer‑to‑peer and to document medical necessity.
• While the appeal is pending, ask about prescription alternatives (Zepbound, Ozempic, Rybelsus, Mounjaro) that might be covered.
• Check Novo Nordisk’s Wegovy support/savings options and Eli Lilly’s Zepbound/Mounjaro patient assistance programs.
• If considering a compounded product, get the compounding pharmacy’s accreditation and test results in writing and discuss risks with your clinician.

If you want, tell me: (a) whether you have commercial insurance, Medicare, or Medicaid, and (b) whether you have diabetes or other weight‑related conditions — I can give more targeted next steps and wording/examples your doctor can use in an appeal.